Drug Detail:Regadenoson (Regadenoson [ re-ga-den-oh-son ])
Drug Class: Cardiac stressing agents
Usual Adult Dose for Radionuclide Myocardial Perfusion Study
0.4 mg rapid IV injection (approximately 10 seconds) into a peripheral vein using a 22 gauge or larger catheter or needle.
Comments: Administer a 5 mL saline flush immediately after injection of this drug. Administer the radionuclide myocardial perfusion imaging agent 10 to 20 seconds after the saline flush. The radionuclide may be injected directly into the same catheter as this drug.
Use: Radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.
Renal Dose Adjustments
No adjustment recommended
Liver Dose Adjustments
No adjustment recommended
Precautions
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
No adjustment recommended
Other Comments
Administration advice: Administer a 5 mL saline flush immediately after injection of this drug. Administer the radionuclide myocardial perfusion imaging agent 10 to 20 seconds after the saline flush. The radionuclide may be injected directly into the same catheter as this drug.
IV compatibility: Do not mix with other medicinal products.
Monitoring:
- Cardiovascular: Continuous ECG and frequent vital sign monitoring should be performed until ECG, heart rate, and blood pressure have returned to pre-dose levels.
Patient advice:
- Instruct patients to avoid consumption of any products containing methylxanthines, including caffeinated coffee, tea or other caffeinated beverages, caffeine-containing drug products, aminophylline and theophylline for at least 12 hours before a scheduled radionuclide myocardial perfusion imaging study.
- Advise patients to call their physician if they experience shortness of breath or difficulty breathing following myocardial perfusion imaging with this drug.
